erlotinib hydrochloride has been researched along with iopromide in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (iopromide) | Trials (iopromide) | Recent Studies (post-2010) (iopromide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,654 | 219 | 653 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| DiPiro, PJ; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M | 1 |
2 trial(s) available for erlotinib hydrochloride and iopromide
| Article | Year |
|---|---|
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Iohexol; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Treatment Outcome; Tumor Burden | 2014 |